Drug intelligence / Profile preview

Broncalt Pediatrico

Development stage: Unknown
Lead developer: Aurora Biofarma
Administration: Inhalation, Intranasal

Overview

Broncalt Pediatrico is a CE-certified Class I medical device developed by Aurora Biofarma for the treatment of pediatric respiratory conditions, including colds, rhinitis, sinusitis, and bronchitis in infants and children. The product is formulated as a nasal solution in single-dose vials containing salsobromoiodic thermal water from the Terme di Monticelli, hyaluronic acid, and grapefruit seed extract. Its mechanism of action involves the modulation of mucus secretion and reduction of local edema by the thermal water, while the grapefruit seed extract provides bacteriostatic and antiviral properties. Hyaluronic acid serves to hydrate and protect the airway mucosa. It is administered via aerosol nebulization or nasal irrigation.

Brand names: Broncalt Pediatrico
Other names: BRONCALT (pediatric)

Beyond the preview

Go deeper on Broncalt Pediatrico.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Broncalt Pediatrico.

Explore the full profile